|drug2263||Norovirus Bivalent (GI.1 / GII.4) Vaccine（low） Wiki||0.71|
|drug2264||Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle） Wiki||0.71|
|drug218||Aluminum adjuvant Wiki||0.71|
There are 2 clinical trials
A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.
Description: Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccinationMeasure: All active AEs within 0-7 days after each dose Time: 7 days
Description: Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time windowMeasure: All non-active collection AEs within 0-28（30） days after each dose Time: 28（30） days
This project is a randomised trial in order to determine if "gamification" can result in behaviour change for healthcare workers in the residential aged care setting. The app is for Age Care and care workers at the front line who are working to protect those most vulnerable to COVID-19. There are 2 groups in this trial on group will receive current and accurate information from an app. The other group will receives the app with the addition of a gamification competent, this will include rewarding experiences for staff doing safety behaviours and wellbeing behaviours. The purpose of the gamification is to create a calming and reassuring experience that injects positivity and joy where possible during this stressful time.
Description: Compare the number of sick leave prior to users utilising the app and at the end of the 4 weeks between the armsMeasure: To compare the hours of sick leave used over the course of the 4-week period post randomisation for each group Time: 4 weeks
Description: Compare the amount of soap/sanitiser used between the armsMeasure: To compare handwashing behaviour Time: 4 weeks
Description: Compare the number of self tests between the two armsMeasure: To compare self-testing rates Time: 4 weeks
Description: Compare the amount of wipes/disinfectant used between the two armsMeasure: To compare the level of surface wipe down Time: 4 weeks
Description: Compare the number of COVID-19 tests between the two armsMeasure: To compare number of COVID-19 tests completed in Facilities Time: 4 weeks
Description: Compare the number of COVID-19 infections between the armsMeasure: To compare the number of COVID 19 infections in facilities Time: 4 weeks
Description: Compare the number of flu and gastroenteritis outbreaks between the armsMeasure: To compare the other types of outbreaks (Flu, gastroenteritis) Time: 4 weeks
Description: Compare the COVID 19 training between the two arms, this is via a self reported surveyMeasure: To compare the awareness of COVID 19 training available to workers in the facilities Time: 4 weeks
Description: Compare the awareness of PPE training of the workers in the two arms, this is captured in self reported surveyMeasure: To compare the awareness of PPE training available to workers in the facilities Time: 4 weeks
Description: Compare the amount of PPE used between the armsMeasure: To compare the levels of PPE material used in Time: 4 weeks
Description: Compare the wellbeing and self-efficacy between the two arms, this is captured in a self reported survey.Measure: To compare the wellbeing and self-efficacy of the two groups Time: 4 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports